Author of

• 10720

  +

  P1.09 - Poster Session 1 - Combined Modality (ID 212)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Combined Modality
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10721

    +

    P1.09-001 - Induction therapy for patients with potentially unresectable NSCLC (adenocarcinoma). Preliminary result. (ID 171)

    09:30 - 16:30  |  Author(s): I. Polyakov
    • Abstract

    Background
    Induction therapy for non-small cell lung cancer has given promising results in a select group of patients, but no prognosis of these patients makes the future uncertain. Using a technique revild EGFR mutations and expression of ALK translocation with follow targeting induction chemotherapy increased the possibility of this technique, even in previously unresectable patients

    Methods
    From 2008 to 2013, 78 patients with potentially unresectable NSCLC was held from 2 to 4 courses of standard (platinabased) induction chemotherapy and 5 patients of targeted chemotherapy with the identification of mutations in EGFR or ALC traslocation. Subsequently assessed resectability of the tumor and in the case of regression of tumors - lung resection

    Results
    In the first group (standard) was 29 patients with adenocarcinoma. Tumor regression was achieved in 3 (10%), partial response in 5 (17%), the rest had stable or progress desease. Toxicity grade 3-4 was observed in 45% of patients. Resectability was achieved in 5 patients (17%). In the second group (target), complete response was achieved in 60% of cases, partial in 1 (20%) and stabilization in 1 patient (20%). Toxicity of chemotherapy is not more than grade 3. Resectability rate was 80%. In operated patients - time to progression was 9 months in the (standard) and 1 year 4 months in the second group (target). Median survival was 11 months versus 18 months.

    Conclusion
    Using the induction of targeted therapy in patients with previously unresectable NSCLC is promising, since the best results were found tolerability, objective response rate and better survival rates of patients.